Elicio Therapeutics, Inc. (NASDAQ:ELTX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $19.75.
A number of equities research analysts have issued reports on the company. Rodman & Renshaw restated a “buy” rating on shares of Elicio Therapeutics in a research note on Monday, June 15th. Wall Street Zen upgraded Elicio Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. LADENBURG THALM/SH SH initiated coverage on Elicio Therapeutics in a report on Thursday, June 18th. They issued a “buy” rating and a $12.00 target price on the stock. HC Wainwright reiterated a “buy” rating on shares of Elicio Therapeutics in a research report on Tuesday, August 18th. Finally, B. Riley Financial started coverage on Elicio Therapeutics in a research report on Wednesday, June 10th. They issued a “buy” rating and a $27.00 price target for the company.
Get Our Latest Analysis on ELTX
Institutional Inflows and Outflows
Elicio Therapeutics Stock Up 4.3%
Elicio Therapeutics stock traded up $0.08 during trading hours on Friday, hitting $1.95. The stock had a trading volume of 23,070 shares, compared to its average volume of 706,334. The stock’s 50-day moving average price is $2.84 and its 200-day moving average price is $7.39. The stock has a market capitalization of $51.12 million, a P/E ratio of -0.92 and a beta of 1.29. Elicio Therapeutics has a 12-month low of $1.71 and a 12-month high of $16.00. The company has a quick ratio of 2.77, a current ratio of 2.77 and a debt-to-equity ratio of 1.20.
Elicio Therapeutics (NASDAQ:ELTX – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.11. Equities research analysts anticipate that Elicio Therapeutics will post -2.1 EPS for the current fiscal year.
Elicio Therapeutics Company Profile
Elicio Therapeutics is a clinical-stage biotechnology company developing cancer immunotherapies designed to activate and strengthen the immune system’s response to tumors. The company’s approach is based on its Amphiphile technology, which is intended to direct therapeutic agents to lymph nodes, where immune responses are initiated and expanded.
Elicio’s leading program, ELI-002, is an investigational therapeutic cancer vaccine targeting common KRAS mutations. The program is being studied in patients with certain solid tumors, including pancreatic and colorectal cancers, with the goal of treating minimal residual disease and reducing the risk of recurrence.
Featured Stories
- Five stocks we like better than Elicio Therapeutics
- 3 Zero-Fee ETFs Worth More Than Their Cost
- 3 Nimble Free Cash Flow Names With Light Assets
- Intel’s Ohio Lifeline? Why the SK Hynix Talks Matter
- Generac Plugs into Amazon for an $8B AI-Powered Deal
Receive News & Ratings for Elicio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elicio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
